Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novavax Inc (NQ: NVAX )

9.350 -0.260 (-2.71%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novavax Inc

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
59 60 Next >
Why COVID Vaccine Demand Might Not Be That Strong
COVID hospitalizations are rising, but they're nowhere near the levels they were at a year or two ago. 
Via The Motley Fool
Exposures COVID-19
Novavax Is a Step Behind, Again. Should You Be Worried?
The FDA still is reviewing Novavax's updated vaccine candidate. 
Via The Motley Fool
Exposures Product Safety
Up 20% in 1 Month, Is This Stock a Buy?
As Covid cases rise, Novavax is getting more attention again. But will the momentum last? 
Via The Motley Fool
Exposures COVID-19
DraftKings Apologizes For 9/11 'Never Forget' Parlay Promotion, Apple Set For Selling 'Made In India' iPhone 15 on Launch Day, MGM Resorts Faces Ongoing Cyber Incident: Today's Top Stories
Benzinga 
Via Benzinga
Tesla, Oracle, Novavax, DraftKings, Pfizer: Why These Five Stocks Are Tending Today
U.S. stocks showcased a positive momentum as the trading day approached its end. The Nasdaq Composite exhibited a notable rise, gaining more than 1% on Monday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Novavax (NVAX) Stock Is Rising
Novavax Inc (NASDAQ: NVAX) shares are trading higher by some 3.9% to $8.36 Monday morning. The stock is gaining amid rising COVID-19 cases in the U.S. 
Via Benzinga
Exposures COVID-19
Why Are Shares of Novavax Soaring Today?
The vaccine maker just gave investors some good news. 
Via The Motley Fool
Moderna, Pfizer Get FDA Nod For Omicron COVID Boosters While Novavax Waits
The U.S. 
Via Benzinga
Exposures COVID-19 Product Safety
Novavax Dives As Pfizer, Moderna Snag First Nods For Covid Boosters
Novavax says it's working with the FDA to answer final requests as part of the agency's review. 
Via Investor's Business Daily
Exposures COVID-19 Product Safety
7 Biotech Stocks to Sell in September Before They Crash & Burn
These are just a few of the top biotech stocks to sell today - especially with each of the firms dealing with legitimate issues. 
Via InvestorPlace
Non-Disappearing COVID Creates Another Chapter For The Pharmaceutical Industry
On Tuesday, UK regulators joined their US and European peers in approving an updated COVID-19 vaccine by Pfizer Inc (NYSE: PFE) and its German partner BioNTech (NASDAQ: BNTX) that targets only the... 
Via Benzinga
Exposures COVID-19
Here's How Moderna's Updated Covid Shot Stacks Up Against Highly Mutated 'Pirola' Variant
Pirola has about 30 mutations compared with previous omicron versions of the virus. 
Via Investor's Business Daily
Exposures COVID-19
This Down-on-Its-Luck Biotech Could Surge 150%, Wall Street Says. Should You Buy the Stock?
Today, Novavax is getting ready to compete in the fall vaccine market -- one that's in transition. 
Via The Motley Fool
Novavax, Zscaler, Digital Brands Group, Asana, Tesla: Why These 5 Stocks Are Drawing Investor Attention Today
Via Benzinga
Why Novavax Stock Rocketed 10% Higher Today
The COVID vaccine maker benefits on a day when worries about a surge intensify with a new case at the White House. 
Via The Motley Fool
Exposures COVID-19
Why Novavax Stock Traded Higher Today
Novavax, Inc. (NASDAQ: NVAX) shares trader higher Tuesday amid rising COVID cases in the US, which has lifted vaccine stocks in recent weeks. 
Via Benzinga
Exposures COVID-19
Coronavirus Cases Are on the Rise -- Should You Buy Vaccine Stocks?
Investors have worried about vaccine revenue in a post-pandemic world. 
Via The Motley Fool
Exposures COVID-19
2 Stocks That Doubled EPS Estimates and Flashing Buy Signals
The second quarter of the 2023 earnings season has drawn to a close. There were many surprises in every sector. However, there were some standout surprises with 
Via MarketBeat
Exposures COVID-19
7 Undervalued Stocks Due for a Massive Short Squeeze
These are the undervalued short squeeze candidates and these stocks represent fundamentally strong growth companies 
Via InvestorPlace
3 Biotech Stocks Due for a Massive Short Squeeze
These are the biotech short squeeze candidates to buy and hold for a massive rally of up to 100% in the coming quarters. 
Via InvestorPlace
Should You Buy Novavax's Stock Before the FDA Approves Its New COVID Shot?
The vaccine's approval could come within weeks. 
Via The Motley Fool
Exposures COVID-19 Product Safety
3 of Wall Street’s Most Shorted Stocks Due for a Massive Short Squeeze
These are the most shorted stocks trading in the U.S. stock market, and any good news could put their short sellers into a serious bind. 
Via InvestorPlace
Why Novavax Stock Was So Healthy on Monday
As the coronavirus threat rises, so too does the vaccine maker's value to investors. 
Via The Motley Fool
Exposures COVID-19
Why NovoCure Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Mobile Infrastructure Corporation (NASDAQ: BEEP) shares jumped 98.7% to $12.02. 
Via Benzinga
Jabil, Boston Scientific, Hersha Hospitality Trust And Other Big Stocks Moving Higher On Monday
U.S. stocks traded higher, with the Dow Jones gaining around 250 points on Monday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
COVID Is Making a Comeback: Should You Buy These 2 Stocks?
Can these companies keep up their recent momentum? 
Via The Motley Fool
Exposures COVID-19
Are These 2 Companies Next for Short Squeezes?
Novavax and Seritage Growth Properties have unusually high short interest and potential short squeeze catalysts. 
Via The Motley Fool
7 Very Oversold Nasdaq Stocks to Buy Right Now
The worries that have pushed the Nasdaq down sharply are overdone. Here are seven oversold Nasdaq oversold Nasdaq investment opportunities. 
Via InvestorPlace
AMTD, VFS, NVAX, DKS, TSLA: Why These 5 Stocks Are Drawing Investor Attention Today
Via Benzinga
APP Stock Price Predictions: Is AppLovin Really Worth $50?
Applovin (APP) stock is in the news Tuesday after the stock got a new price target from Jefferies analyst Andrew Uerkwitz. 
Via InvestorPlace
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
59 60 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.